CSC's DVC Wins $32.3 Million NIAID Contract to Establish Phase 1 Clinical Trial Unit
News Jul 15, 2008
CSC has announced that DynPort Vaccine Company LLC (DVC), a CSC company, has received a contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to establish and operate a Phase 1 clinical trial unit for infectious disease therapeutics.
The contract is valued at approximately $32.3 million over a seven-year period. DVC is teaming with Quintiles Transnational Corp. to complete this work.
Under the terms of the agreement, DVC and Quintiles will manage a Phase 1 clinical trial unit to assess the safety of investigational therapeutic products being studied by NIAID, and determine pharmacokinetic and pharmacodynamic properties of up to four new investigational products per year.
As the prime contractor, DVC will provide overall project management, clinical operations management, quality assurance and co-development of protocols. Quintiles will provide Phase 1 clinical research and support services for the implementation and conduct of approved Phase 1 clinical trial protocols.
Trials will include therapeutic candidates for a broad range of infectious diseases. Investigational products tested could include measures to protect against viral (other than HIV), bacterial, parasitic and fungal pathogens, including NIAID priority biodefense pathogens and emerging and re-emerging infectious diseases.
"DVC and Quintiles have an established history of success - both individually and as partners - in clinical trial management of medical countermeasures," said Dr. Robert V. House, president of DVC. "DVC has successfully advanced eight products into clinical trials in the last 10 years. This represents an expansion of DVC's capabilities in pharmaceutical product development."